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ABSTRACT
The in vivo chronic and in vitro acute effects of di(2-
ethylhexyl) phthalate (DEHP) on the reproductive function of
peroxisome proliferator-activated receptor gamma (PPARG)
were studied in rabbit corpora lutea (CL) at early stage (Day
4), midstage (Day 9), and late stage (Day 13) of pseudopreg-
nancy. The rabbits were in vivo treated with DEHP for 15 days
before induction of pseudopregnancy. Immunohistochemistry
provided evidence for the presence of PPARG, prostaglandin
endoperoxide synthase 1 (PTGS1), PTGS2, prostaglandin E2-9-
ketoreductase (PGE2-9-K), and 3beta-hydroxysteroid dehydro-
genase (3beta-HSD) in all the luteal cells during pseudopreg-
nancy. DEHP decreased progesterone plasma levels and CL
production in all the luteal stages and PPARG protein and gene
expressions in early and mid-CL. DEHP in vivo treatment
reduced PTGS2 protein expression at the late stage and that of
PGE2-9-K at all the stages, whereas PTGS1 and 3beta-HSD were
not affected. In in vitro cultured CL, DEHP alone, the PPARG
antagonist T0070907 alone, or DEHP plus T0070907 diminished
progesterone production and 3beta-HSD activity and increased
PGF2alpha and PTGS2 in early and mid-CL, whereas DEHP plus
the PPARG agonist 15d-PGJ2 did not affect these hormones and
enzymes. All the in vitro treatments did not affect PGE2
secretion as well as PTGS1 and PGE2-9-K enzymatic activities
in all the luteal stages. These results provided evidence that
DEHP favors functional luteolysis of pseudopregnant rabbit CL,
with a mechanism that seems to involve PPARG expression
down-regulation, an increase of PTGS2 activity and prostaglan-
din F2alpha secretion, 3beta-HSD down-regulation, and de-
crease in progesterone.
3beta-HSD, corpora lutea, corpus luteum, DEHP, endocrine
disruptors, PGF2alpha, PPARG, PTGS2, progesterone/
progesterone receptor, prostaglandins, rabbit
INTRODUCTION
Animals housed in confined habitats face a wide range of
potentially harmful biotic and abiotic environmental stressors,
among them endocrine-disrupting chemicals (EDCs). Dietary
intake of traces of these contaminants contributes to varied
male and female animal health problems worldwide [1–3].
Di(2-ethylhexyl) phthalate (DEHP) is extensively used as a
plasticizer in many mass-produced products, including food
packaging, toys, electrical equipment, medical devices, paints,
and cosmetics [4, 5]. Phthalates are not chemically bound to
plastic materials and so are easily leached into the environment
with time and use [5]. DEHP is the most widespread phthalate
in the environment and easily contaminates livestock feed,
causing profound and long-lasting changes of reproductive
functions [6–10]. While the exact mechanisms by which
phthalates induce these effects are not clear, they may involve
interaction with multiple receptor systems, including peroxi-
some proliferator-activated receptors (PPARs) [11–14].
PPARs, a family of three (alpha, delta, and gamma) nuclear
receptor/transcription factors, are involved in several processes,
some of which are critical for normal ovarian function [15].
PPARs have been identified in the ovary of many mammalian
species, such as rats [16], mice [17, 18], swine [19], ovine [20],
cattle [21, 22], rabbits [23, 24], and humans [25, 26]. It has
recently been suggested that PPAR gamma (PPARG) plays a
luteotropic role in pseudopregnant rabbits [24]. Various studies
showed that EDCs, such as DEHP, bind to PPARs and that the
interaction with PPARG interferes with several reproductive
functions [14, 27].
The renaissance of the laboratory rabbit as a reproductive
model for human health [28] suggests that the corpora lutea
(CL) of this species are a good model for investigating both
long- and short-term effects of DEHP on mechanisms
regulating luteal function because ovulation can be induced
by exogenous gonadotropin-releasing hormone (GnRH) ad-
ministration [29] and the CL can be staged precisely.
Therefore, the goal of the present investigation was to examine
in vivo and in vitro both the chronic and acute effects of DEHP
on rabbit CL during early, mid, and late luteal stages of
pseudopregnancy. In particular, the experiments were per-
formed to better understand the effects of DEHP on the protein
and gene expressions of PPARG, on the production of
progesterone, prostaglandin E2 (PGE2), and PGF2alpha, and
on the activity of the enzymes involved in the regulation of CL
life span: 3beta-hydroxysteroid dehydrogenase (3beta-HSD),
prostaglandin endoperoxide synthase 1 (PTGS1), PTGS2, and
PGE2-9-ketoreductase (PGE2-9-K).
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MATERIALS AND METHODS
Reagents and Hormones
Mouse monoclonal anti-PPARG (sc-7273) and mouse monoclonal anti-
3beta-HSD (sc-100466) were obtained from Santa Cruz Biotechnology; mouse
monoclonal anti-PTGS1 and mouse monoclonal anti-PTGS2 were purchased
from Acris Antibodies and BD Transduction Laboratories, respectively; goat
polyclonal anti-PGE2-9-K (CBR1) was purchased from Abcam. Biotin-
conjugated goat anti-mouse immunoglobulin G (IgG) and biotin-conjugated
rabbit anti-goat IgG secondary antibodies were obtained from Santa Cruz
Biotechnology. Avidin-biotin complex (ABC Kit), chromogen 3,30-diamino-
benzidine tetrachloride, and mouse and goat IgG were purchased from Vector
Laboratories.
Random hexamer primers, deoxyribonuclease I (DNase I Amplification
Grade), RNase H-reverse transcriptase (Superscript III Reverse Transciptase),
Escherichia coli RNase H, DNA ladders as well as reagents for the isolation
and purification of total RNA (TRIzol), Taq DNA polymerase (Platinum),
RNase-free tubes, RNase-free water, and deoxynucleotide triphosphates were
obtained from Invitrogen. Primers for 18S rRNA and corresponding
competimers (QuantumRNA 18S Internal Standards) as well as PPARG were
also acquired from Invitrogen. Tritiated hormones and [3H] arachidonic acid
(AA) were purchased from Amersham Biosciences Ltd., while progesterone,
PGF2alpha, and PGE2 antisera, DEHP, dimethylsulfoxide, and nonradioactive
hormones came from Sigma. The endogenous PPARG agonist 15d-PGJ2 and
the selective antagonist T0070907 were purchased from Tocris Bioscience.
Selective PTGS2 inhibitor (NS-398) and nonselective PTGS inhibitor
(acetylsalicylic acid) were purchased from Sigma-Aldrich. Incubation wells
were obtained from Becton Dickinson Co., while medium 199 and Earle
Balanced Salt Solution were from GIBCO. HEPES and bovine serum albumin
(BSA) were purchased from Sigma, whereas all the other pure grade chemical
and reagents were obtained locally. The following hormonal preparations were
administered via intramuscular injection: eCG (Folligon; Intervet) and GnRH
analog (Receptal; Hoechst-Roussel Vet).
Animals and Hormonal Regimen
Sexually mature New Zealand white female rabbits (3.5–4 kg body weight
and 5 mo of age), raised in premises owned by the University of Perugia were
used for all the experiments. The rabbits were housed individually in wire mesh
cages under controlled light (14L:10D, lights off at 2100 h) and temperature
(188C–248C) conditions. Each animal had free access to food and water.
Pseudopregnancy was induced with 20 international units eCG followed 3 days
later by 0.8 lg GnRH analog (buserelin) [30]. The day of buserelin injection
was designated as Day 0. The protocols for the use of the animals for these
experiments were approved by the Bioethics Committee of the University of
Perugia.
In Vivo Experiments
The rabbits (n¼ 15/group) were daily administered orally either DEHP in
corn oil (treated group, 1 mg/kg/day in 0.2 ml/kg body weight) or corn oil alone
(control group) for 15 days before induction of ovulation by buserelin injection.
We purposely employed the NOAEL (no observed adverse effect level) dose
suggested by Andrade et al. [31] and, more recently, by Kay et al. [32] to avoid
any possible pharmacological actions. Feed intake and body weight were
recorded every day. From each rabbit, blood samples were collected by venous
puncture of the marginal ear vein [33]; the first just before DEHP treatment
(Day15 before ovulation) and then Day7, Day 0 (buserelin injection), and
Days 4, 9, and 13 of pseudopregnancy. The samples, collected in
ethylenediaminetetraacetic acid (EDTA) vacutainers, were centrifuged at
3000 3 g for 15 min, and plasma were stored frozen until assayed for
progesterone concentrations. No differences were evidenced in the number of
CL between treated and nontreated rabbits.
Tissue Collection and Processing
On Days 4 (early stage), 9 (midstage), and 13 (late stage) of
pseudopregnancy, animals (n ¼ 6 control and n ¼ 6 treated for each luteal
stage) were euthanized by cervical dislocation in accordance with the
guidelines and principles for the care and use of research animals. Upon
euthanasia, the reproductive tracts were promptly removed and thoroughly
washed with saline. After a few minutes, the CL were excised from ovaries and,
after careful dissection of nonluteal tissue by fine forceps under stereoscopic
magnification, immediately processed for in vitro experiments or, after rinsing
with RNase-free PBS, frozen at808C for later evaluation of gene and protein
expression. For the immunohistochemical analysis, the ovaries of two animals
for each luteal stage were fixed by immersion in 4% (w/v) formaldehyde in
PBS (pH 7.4) for 24 h at room temperature and subsequently processed
following routine tissue preparation procedures [34, 35].
Immunohistochemistry
The immunohistochemical procedures were performed as previously
reported [36]. Ovaries were embedded in paraffin and sectioned serially at a
thickness of 5 lm. Sections were deparaffinized, rehydrated through graded
concentrations of alcohol to distilled water, and submitted to antigen retrieval
by microwaving in 1 mM EDTA (pH 8.0) for PPARG and in 10 mM citrate-
buffered solution (pH 6.0) for PTGS1, PTGS2, and PGE2-9-K, for 10 min. The
slides were then cooled to room temperature. After rinsing with TBS (Tris-
buffered saline), they were dipped in 3% H
2
O
2
in methanol for 1 h to quench
the endogenous peroxidase activity and rinsed in TBS. Background labeling
was prevented by incubating the sections with normal goat serum (for PPARG,
PTGS1, PTGS2, and 3beta-HSD) and with normal rabbit serum (for PGE2-9-
K) diluted 1:10 for 1 h at room temperature. Subsequently, the sections were
incubated overnight at 48C in a moist chamber with the following primary
antisera diluted in TBS containing 0.2% Triton X-100 and 0.1% BSA: anti-
PPARG (1:50), anti-PTGS1 (1:50), anti-PTGS2 (1:50), anti-PGE2-9-K (1:500),
and anti-3beta-HSD (1:100).
The next day, the slides were rinsed three times in TBS (5 min each),
treated again with normal goat or rabbit serum and incubated with biotin-
conjugated goat anti-mouse (for PPARG, PTGS1, PTGS2, and 3beta-HSD) or
biotin-conjugated rabbit anti-goat (for PGE2-9-K) secondary antibodies diluted
1:200 for 30 min at room temperature. After TBS washes, the slides were
exposed to the ABC Kit for 30 min and rinsed again with TBS. The peroxidase
activity sites were visualized using the 3,30-diaminobenzidine tetrachloride kit
as the chromogen; the sections were rinsed with distilled water and, in some
cases, were counterstained with Mayer hematoxylin, washed in running tap
water, dehydrated by passing through graded ethanol (70%, 95%, and 100% v/
v), cleared in xylene, and finally mounted with Eukitt medium for light
microscopy. Tissue sections in which the primary antibody was omitted or
substituted by mouse or goat IgG were used as negative controls of nonspecific
staining. The intensity of immunostaining was assessed and compared
microdensitometrically as previously described [37] using an image analysis
system (IAAS 2000 image analyzer; Delta Sistemi).
RT-PCR
Total RNA was extracted from CL of three rabbits for each luteal stage of
treated and control animals as previously described [38]. Five micrograms of
total RNA were reverse transcribed in 20 ll of SuperScript III Reverse
Transcriptase cDNA synthesis mix using random hexamer according to the
protocol provided by the manufacturer. Genomic DNA contamination was
checked by developing the PCR without reverse transcriptase. The PCR
reaction (25.0 ll) was performed with 0.2 ll Taq DNA polymerase (5 units/ll),
1.0 ll deoxynucleotide triphosphates (10 mM), 1.5 ll MgCl
2
(50 mM), 5.0 ll
Taq buffer 103, 2.0 ll mixed primers for PPARG gene (product size 200 bp;
forward 5 0-TGAAGGATGCAAGGGTTTCT-3 0, reverse 5 0-CCAA
CAGCTTCTCCTTCTCG-30, accession no. U84893.1), and 18S housekeeping
gene (product size 489 bp, forward 50-TCAAGAACGAAAGTCGGAGGTT-
30, reverse 50-GGACATCTAAGGGCATCA-30) with competimers (1:9 v/v)
[24].
Cycling conditions consisted of an initial denaturizing cycle at 948C for 75
sec, followed by 35 cycles for each target gene at 948C for 15 sec, 608C for 30
sec, 728C for 45 sec, and a final extension step at 728C for 10 min [24]. Within
each experiment, the complete set of samples was processed in parallel in a
single PCR using aliquots of the same PCR master mix. The amplified PCR-
generated products (20 ll of 25 ll total reaction volume) were analyzed by
electrophoresis on 2% agarose gel using ethidium bromide staining. Analysis of
amplification products was carried out as reported elsewhere [38]. The
amplified products, collected from agarose gel after electrophoresis, were
purified with Nucleospin Extract II kit, and their identities were confirmed by
DNA sequencing with the Sanger method.
Western Blot Analysis
Total luteal proteins were extracted from 100 mg of CL collected at the
midstage of pseudopregnancy as previously described [39]. Briefly, 20 lg
proteins were separated by SDS-PAGE, and the blocked membrane was then
probed with mouse monoclonal anti-PPARG, mouse monoclonal anti-3beta-
HSD, mouse monoclonal anti-PTGS1, mouse monoclonal anti-PTGS2 and goat
polyclonal anti-PGE2-9-K overnight at 48C. All the antibody dilutions were
1:1000. After being washed with TBS, the membrane was incubated with
PARILLO ET AL.
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horseradish peroxidase-labeled goat anti-mouse IgG and rabbit anti-goat IgG
secondary antibodies (1:20 000 dilution) at room temperature for 1 h.
In Vitro Experiments
A previously reported method was used for the in vitro study [40, 41]. Day
4, 9, or 13 CL of control (in vivo untreated) and DEHP in vivo treated rabbits
(four rabbits per treatment for each luteal stage) were randomly distributed (one
CL/well) into incubation wells (Becton Dickinson Co.) in 1 ml of culture
medium 199 with Earle Balanced Salt Solution containing 2.2 mg/ml sodium
bicarbonate, 2.3 mg/ml HEPES, and 3% BSA (w/v), referred to here as M199.
Before treatment, the CL was quartered inside each well using fine forceps.
Stock solution of DEHP was prepared at concentrations of 2 mM in
dimethylsulfoxide [42]. Each set of incubation wells was divided into six
experimental groups, each formed of six wells as follows: 1) CL of in vivo
untreated rabbit (control) in medium alone; 2) CL of DEHP in vivo treated
rabbit in medium alone; 3) control CL in medium plus PPARG agonist (200
nM 15d-PGJ2); 4) control CL in medium plus DEHP (100 lM); 5) control CL
in medium plus DEHP (100 lM) plus 15d-PGJ2 (200 nM); and 6) control CL
in medium plus DEHP (100 lM) plus PPARG antagonist (T0070907, 50 nM).
The culture plates were incubated at 378C in air with 5% CO
2
. The media of
each well were collected after 4 h of incubation and stored immediately at
208C for later determination of progesterone, PGF2alpha, and PGE2.
Preliminary evidence led to our choosing the incubation conditions and the
minimum effective dose for 15d-PGJ2 and DEHP used in the present in vitro
study (data not shown).
To evaluate whether DEHP treatment in vitro has any acute effect on
PPARG expression, CL harvested at Days 4, 9, and 13 of pseudopregnancy
from control rabbits (three rabbits for each luteal stage) were randomly
distributed (one CL/well) into incubation wells in 1 ml of culture medium
M199 alone (control) or medium containing DEHP (100 lM, treated). After 4 h
of incubation, the CL were collected, rinsed with RNase-free PBS, and
processed for RT-PCR analysis.
Hormone Determination
Progesterone, PGF2alpha, and PGE2 were determined following previously
reported radioimmunoassay protocols [43]. Intra- and interassay coefficients of
variation and minimum detectable doses were: progesterone (6.1%, 8.9%, 11
pg); PGF2alpha (7.5%, 12.4%, 18 pg); and PGE2 (6.4%, 12.2%, 16 pg).
Enzyme Activity Determination
Activities for PTGS1 and PTGS2 were determined by measuring the
disappearance of the radiolabeled substrate [3H]AA using a previously reported
method [44, 45]. The selective PTGS2 inhibitor (NS-398, 1 lM) and
nonselective PTGS inhibitor (acetylsalicylic acid, 1 mM) were used. For each
sample, PTGS1 activity was determined by calculating the rate of loss of
[3H]AA incubated with the selective PTGS2 inhibitor. Conversely, the PTGS2
activity of each corresponding sample was determined by calculating the rate of
loss of [3H]AA incubated without the selective PTGS2 inhibitor and subtracting
from this the value for PTGS1. The values for PTGS1 and PTGS2 were
corrected by subtracting the [3H]AA disappearance values resulting from other
enzymatic activities and to nonenzymatic reactions.
The PGE2-9-K activity was determined by measuring the conversion of
[3H]PGE2 into [3H]PGF2alpha using a previously reported modified method
[45], whereas that of 3beta-HSD was determined by measuring the conversion of
[3H]pregnenolone into [3H]progesterone [24]. Briefly, each pool of CL was
homogenized in 1 ml cold fresh homogenizing buffer (20 mM K
2
HPO
4
, 1 mM
EDTA, and 10 mM beta-mercaptoethanol, pH 7.4). The total homogenate was
filtered and immediately used for the assay of enzymatic activity. One hundred
microliters of homogenate and 50 ll of homogenizing buffer containing 150 000
dpm [3H]pregnenolone and NADPH (3 mg/ml) were added to the incubation
tube. The mixture was incubated at 378C for 10 min. Termination was achieved
by addition of 100 ll 0.1 M HCl. Steroids were extracted with diethyl ether and
resuspended with 500 ml RIA buffer (74.5 mM Na
2
HPO
4
, 12.5 mM Na EDTA,
and 0.1% gelatine, pH 7.5). Two hundred microliters of RIA buffer containing
progesterone specific antiserum were added to duplicated samples, and the
mixture was incubated at 48C for 16 h. The [3H]progesterone-antiserum bound
fraction was separated with charcoal-dextran suspension, and the radioactivity
was quantified by liquid scintillation counting.
Statistical Analysis
All the data were examined by Levene test and one-way ANOVA followed
by Tukey post hoc comparisons. Differences were considered significant at P,
0.01.
RESULTS
Immunohistochemistry
In both control and treated rabbits, PPARG immunoreac-
tivity was localized intensely in the perinuclear cytoplasm and
with lesser intensity in the nucleus of luteal cells (Fig. 1). In
does treated with DEHP, PPARG immunoreactivity decreased
(P , 0.01) in early CL and mid-CL compared to controls (Fig.
1). At late stage of pseudopregnancy, the majority of the nuclei
of luteal cells were immunonegative in both control and treated
CL (Fig. 1). The blood vessels were always negative (Fig. 1).
In control animals, PTGS1 immunostaining was intensely
evidenced in the perinuclear cytoplasm and weakly evidenced
in the nucleus of all luteal cells at the early stage of
pseudopregnancy (Fig. 2). The immunodensity decreased (P
, 0.01; Fig. 2) from early to late stages (Fig. 2); in particular,
at the late stage, the cytoplasm luteal cell immunoreactivity
diminished whereas that of the nucleus increased (Fig. 2).
Immunosignals for PTGS1 were also observed in the nucleus
of endothelial cells during all the phases of CL. In the treated
animals, PTGS1 immunodensitometric analysis showed that
the treatment with DEHP did not produce significant effects
compared to controls (Fig. 2).
Immunosignals of PTGS2 were detected in the cytoplasm of
all luteal cells during all the CL stages of pseudopregnancy in
control animals (Fig. 3); the immunodensity was higher (P ,
0.01; Fig. 3) at late and mid stages (Fig. 3). Additionally,
endothelial cells of arteries, but not of veins (Fig. 3), displayed
intense immunoreactivity during all the CL stages considered.
In treated does, PTGS2 immunosignals decreased (P , 0.01;
Fig. 3) only at late stage compared to controls (Fig. 3). The
immunopositive reaction of arterial endothelial cells was not
modified by DEHP treatment (Fig. 3).
In control animals, PGE2-9-K immunosignals were ob-
served in the cytoplasm and nucleus of luteal cells during all
the CL stages of pseudopregnancy (Fig. 4); the immunodensity
was higher (P , 0.01) (Fig. 4) at the early stage. The
immunopositive reaction was also detected in the nuclei of
endothelial, smooth musculature, and stromal cells of both
veins and arteries. In treated does, PGE2-9-K immunoreactivity
decreased (P , 0.01) during all the CL stages compared to
controls (Fig. 4); the densitometric levels of early treated does
were similar to that of middle and late control animals (Fig. 4).
The immunostaining of endothelial, smooth musculature, and
stromal cells of blood vessels were similar to the controls.
In control animals, 3beta-HSD immunosignals were local-
ized in the cytoplasm of all the luteal cells (data not shown).
The immunodensity did not change in all the luteal stages (data
not shown). In treated animals, 3beta-HSD immunodensito-
metric analysis showed that the treatment with DEHP did not
produce significant effects compared to controls (data not
shown). The blood vessels were always negative (data not
shown). No staining was detectable in negative control rabbit
ovary, where the primary antibodies were omitted or
substituted with mouse or goat IgG (data not shown).
Western Blot Analysis
The Western blot analyses confirmed the specificity of the
antisera used for immunohistochemistry in CL samples with a
single band for each protein examined at approximately 55 kDa
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FIG. 1. Immunohistochemical detection of PPARG (PPARc) in CL collected from untreated (control) and DEHP-treated rabbits at early, mid, and late
stages of pseudopregnancy. A–C) Control animals. D–F) DEHP-treated does. G) Immunodensitometry. Data are expressed in arbitrary units; values are the
means 6 SD of 30 replicates; different letters above the bars indicate significantly different values (P , 0.01) among control CL; and the asterisks indicate
significantly different values (P , 0.01) versus the control. Original magnifications320, bars¼ 20 lm.
PARILLO ET AL.
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FIG. 2. Immunohistochemical detection of PTGS1in CL collected from untreated (control) and DEHP-treated rabbits at early, mid, and late stages of
pseudopregnancy. A–C) Control animals. D–F) DEHP-treated rabbits. The arrows indicate the positive reaction of the nucleus of endothelial cells. G)
Immunodensitometry. The data are expressed in arbitrary units; values are the means 6 SD of 30 replicates; different letters above the bars indicate
significantly different values (P , 0.01) among control CL. Original magnifications320, bars¼ 20 lm.
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FIG. 3. Immunohistochemical detection of PTGS2 in CL collected from untreated (control) and DEHP-treated rabbits at early, mid, and late stages of
pseudopregnancy. A–C) Control animals. D–F) DEHP-treated does showing the immunoreactivity of arterial endothelial cells (arrows) and the
immunonegative responses of veins (arrowheads). G) Immunodensitometry. The data are expressed in arbitrary units; values are the means 6 SD of 30
replicates; different letters above the bars indicate significantly different values (P , 0.01) among control CL; and the asterisks indicate significantly
different values (P , 0.01) versus the control. Original magnifications320, bars¼ 20 lm.
PARILLO ET AL.
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FIG. 4. Immunohistochemical detection of PGE2-9-K in CL collected from untreated (control) and DEHP-treated rabbits at early, mid, and late stages of
pseudopregnancy. A–C) Control animals. D–F) DEHP-treated does. The arrows indicate the positive reaction of the nuclei of endothelial, smooth muscle,
and stromal cells of blood vessels. G) Immunodensitometry. The data are expressed in arbitrary units; values are the means6 SD of 30 replicates; different
letters above the bars indicate significantly different values (P , 0.01) among control CL; and the asterisks indicate significantly different values (P, 0.01)
versus the control. Original magnifications320, bars¼ 20 lm.
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for PPARG, 70 kDa for PTGS1, 70 kDa for PTGS2, 35 kDa
for PGE2-9-K, and 42 kDa for 3beta-HSD (data not shown).
PPARG RT-PCR
In control rabbits, PPARG transcript was expressed in the
CL at different stages of pseudopregnancy with the lowest
abundance (P , 0.01) at the late stage of pseudopregnancy
(Fig. 5, upper panels). Daily administration of DEHP for 15
days before ovulation reduced (P , 0.01) PPARG expression
in CL collected at early and mid stages of pseudopregnancy
(Fig. 5, left panels). In CL harvested from control rabbits and
cultured in vitro for 4 h, addition of DEHP to the medium
reduced (P , 0.01) PPARG expression in early and mid-CL
(Fig. 5, right panels).
In Vivo Hormone Plasma Levels
Daily administration of DEHP did not affect feed intake and
body weight of the treated rabbits (data not shown). Treatment
with DEHP did not interfere with ovulation as assessed by
progesterone profiles (Fig. 6), whereas it induced a decrease (P
, 0.01) of plasma progesterone concentrations in rabbits
during early, mid, and late stages (Fig. 6).
In Vitro Hormone Productions
Progesterone release from the CL of control rabbits was the
lowest (P , 0.01) at the early stage and the highest (P , 0.01)
at midstage (Fig. 7). The amounts of progesterone released by
CL obtained from rabbits treated with DEHP was lower (P ,
0.01) than those of control (in vivo untreated) CL in all the
luteal stages (Fig. 7). Addition of 15d-PGJ2 into the medium
increased (P , 0.01) while that of DEHP, T0070907, or DEHP
plus T0070907 reduced (P , 0.01) progesterone in vitro
secretion by control CL at the early and mid stages of
pseudopregnancy (Fig. 7). Addition of DEHP plus 15d-PGJ2
did not modify progesterone in vitro secretion (Fig. 7).
Control basal PGF2alpha secretion was higher in late CL (P
, 0.01) than in early and mid-CL, and secretion of mid-CL
was higher (P , 0.01) than that of early stage (Fig. 7). In vivo
treated rabbit CL released greater amounts of PGF2alpha (P ,
0.01) in vitro compared to control CL in all the luteal stages
(Fig. 7). The addition of 15d-PGJ2 reduced (P , 0.01) and
DEHP, T0070907, or DEHP plus T0070907 increased (P ,
FIG. 5. Expression profile of PPARG mRNA in CL of in vivo DEHP-treated rabbit (left panels) and in in vitro DEHP-treated CL (right panels) collected at
early, mid, and late stages of pseudopregnancy. The lower panels show a representative photograph of a 2% agarose ethidium bromide-stained gel used to
analyze the PCR products. The sizes of the amplified products are shown on the left of the gel. LD is the kilobase DNA marker. The other lanes identify the
corresponding pseudopregnancy stages of control (C) and DEHP-treated (T) animals. Lane PCR represents a negative control of nonreverse-transcribed
RNA submitted to PCR amplification.The upper panels show the data derived from densitometric analyses of the gels. For each luteal stage, the values
(means 6 SD) combine the results from three different rabbits and are reported in arbitrary units of PPARG mRNA relative to that of 18S used as the
internal standard. Different letters above the bars indicate significantly different values (P , 0.01) among control CL, and the asterisks indicate
significantly different values (P , 0.01) versus the control.
FIG. 6. Progesterone plasma levels in pseudopregnant rabbits in vivo
chronically treated with DEHP for 15 days before induced ovulation.
Values are the means 6 SD of 15 replicates. The asterisks above the bars
indicate significantly different values (P , 0.01) versus the control.
PARILLO ET AL.
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FIG. 7. In vitro releases of progesterone and PGF2alpha by CL collected from in vivo untreated (control) and DEHP in vivo treated rabbits at early, mid,
and late stages of pseudopregnancy. The in vitro acute effects of 15d-PGJ2 (PPARG agonist), DEHP, DEHP plus 15d-PGJ2, and DEHP plus T0070907
(PPARG antagonist) were obtained on CL from in vivo untreated rabbits. Values are the means 6 SD of six replicates. Different letters above the bars
indicate significantly different values (P , 0.01) among control CL, and the asterisks indicate significantly different values (P , 0.01) versus the control.
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0.01) PGF2alpha in vitro secretion of control CL at the early
and mid stages of pseudopregnancy (Fig. 7), whereas these
treatments did not affect late CL. Addition of DEHP plus 15d-
PGJ2 did not modify PGF2alpha in vitro secretion (Fig. 7).
Control basal PGE2 secretion was higher (P , 0.01) in
early CL (844 6 164 pg/mg protein) than in mid-CL (356 6
116 pg/mg protein) and late CL (295 6 98 pg/mg protein). In
vivo treated rabbit CL released in vitro amounts of PGE2
similar to those of control CL in all the luteal stages (data not
shown). All the in vitro treatments did not modify PGE2
secretion of control CL in any of the luteal stages (data not
shown).
Luteal Enzyme Activities
Control basal PTGS1 activity was higher (P , 0.01) in late
CL (15 823 6 2314 dpm/mg protein) CL than in early CL
(6345 6 776 dpm/mg protein) and mid-CL (7241 6 9564
dpm/mg protein). In vivo treated rabbit CL showed PTGS1
activity similar to those of control CL in all the luteal stages
(data not shown). All in vitro treatments did not modify PTGS1
activity of control CL in any of the luteal stages (data not
shown).
Control basal PTGS2 activities were higher in late CL (P ,
0.01) than in early and mid-CL (Fig. 8), and PTGS2 activity of
mid-CL was higher (P , 0.01) than that of early ones (Fig. 8).
DEHP in vivo treatment increased (P , 0.01) PTGS2 activity
at early and mid stages of pseudopregnancy (Fig. 8). In vitro
treatment with 15d-PGJ2 reduced (P , 0.01) and with DEHP,
T0070907, or DEHP plus T0070907 increased (P , 0.01)
PTGS2 activity at early and mid stages of pseudopregnancy
(Fig. 8). In vitro addition of DEHP plus 15d-PGJ2 did not
modify PTGS2 activity (Fig. 8).
Control basal PGE2-9-K activity were higher (P , 0.01) in
late CL (40 095 6 3787 dpm/mg protein) than in early CL
(3407 6 758 dpm/mg protein) and mid-CL (13 651 6 1947
dpm/mg protein). In vivo treated rabbit CL showed PGE2-9-K
activity similar to those of control CL in all the luteal stages
(data not shown). All the in vitro treatments did not modify
PGE2-9-K activity of control CL in any luteal stages (data not
shown).
Control basal 3beta-HSD activity was higher in mid-CL (P
, 0.01) than those of early and late CL, and activity in early
CL was higher (P, 0.01) than that of late ones (Fig. 8). DEHP
in vivo treatment reduced (P , 0.01) 3beta-HSD activity at
early and mid stages of pseudopregnancy (Fig. 8). In vitro
treatment with 15d-PGJ2 increased (P , 0.01) and with
DEHP, T0070907, or DEHP plus T0070907 reduced (P ,
0.01) 3beta-HSD activity at early and mid stages of
pseudopregnancy (Fig. 8). In vitro addition of DEHP plus
15d-PGJ2 did not modify 3beta-HSD activity (Fig. 8).
DISCUSSION
PPARG has been found in both granulosa and theca cells
and also in CL of rodents, ruminants [16, 20, 46], and
pseudopregnant rabbits [24], facts that suggest that it may have
a role in the regulation of reproduction. In cattle CL, the
PPARG gene and protein expressions increased after ovulation,
but decreased in case of fertilization or embryo implantation
failure [47, 48]. In rabbit CL, PPARG exerted a luteotrophic
role via 3beta-HSD up-regulation and PTGS2 down-regulation,
with the consequent increase of progesterone production and
concurrent decrease of PGF2alpha synthesis [24].
Using immunohistochemistry, positive staining for PPARG
was identified in the cytoplasm and nucleus of all the luteal
cells during the three stages of pseudopregnancy, with an
evident immunonegative response in the majority of nuclei in
late CL as already reported [24]. In good agreement with these
results, semiquantitative/relative RT-PCR showed the lowest
levels of PPARG mRNA in late CL. The in vivo DEHP
treatments determined a notable drop in PPARG immunosig-
nals in early and mid-CL, whereas they had no effect on late
CL when PPARG expression was already down-regulated as
well as in control rabbits. The PPARG gene expression also
was decreased by in vivo and in vitro DEHP treatments in early
and mid-CL.
Previous studies showed that the activation of PPARG
induces an up-regulation of ovarian progesterone production
[27]. Indeed, PPARG activation increased progesterone
secretion in rat granulosa cells [16], in porcine theca and
bovine luteal cells [48], and in pseudopregnant rabbit CL [24].
Here we found that prolonged DEHP administration before
ovulation clearly affected peripheral plasma progesterone
concentrations also during the subsequent pseudopregnancy.
In fact, progesterone levels were much lower than those of
control rabbits during early, mid, and late luteal phases. In
agreement with these data obtained in vivo, also the basal in
vitro release of progesterone by CL harvested from DEHP-
treated rabbits was lower than that of controls for each luteal
stage. It remains to be established whether the antiluteotropic
effect of DEHP, observed here when administered chronically
before ovulation, is due to a direct action on theca and/or
granulosa cells that, following luteinization and CL develop-
ment, will synthesize less progesterone or whether it is related
to an indirect action mediated by a reduced synthesis of
estrogens, a luteotropic hormone in rabbits, by follicles. On the
other hand, because the DEHP administration was orally
performed with a consequent systemic distribution, we cannot
exclude that the down-regulation of CL progesterone synthesis
could be indirectly due also to the DEHP effects on other
tissues and/or organs.
Recently, Kay et al. [32], reviewing the reproductive and
developmental effects of phthalates in mammal females,
proposed for DEHP a NOAEL of 1.0 mg/kg/day, on the basis
of studies done on marmosets, mice, and rats, whereas much
higher doses were required to cause observable reproductive
disorders. More broadly, these authors reported that the animal
literature shows that adverse reproductive effects occur at high
doses while concentrations representative of human exposure
do not produce reproductive or developmental effects, thereby
questioning the relevance of current animal models. In the
present study, however, we found that DEHP when adminis-
tered in vivo at the same NOAEL dose influenced the
reproductive function of rabbits. Thus, while confirming the
high variability of DEHP effects among mammal species, our
findings suggest that the rabbit is a suitable animal model for
the study of DEHP actions on the reproductive function, being
much more sensitive than other species insofar examined.
The in vitro experiment showed that addition to the culture
medium of DEHP, PPARG endogenous agonist (15d-PGJ2), or
its selective antagonist (T0070907) affected progesterone
production in early and mid-CL obtained from untreated
rabbits, but they had no effects on late CL. The lack of in vitro
acute effects of DEHP and PPARG agonist and antagonist on
late CL may be a result of the lower levels of PPARG protein
and gene expression found in these luteal cells as demonstrated
by densitometry and PCR in control animals. In particular, this
PPARG decrease can be ascribed to the loss of this receptor in
the luteal cell nucleus during the late stage as revealed by
immunohistochemistry.
Our in vitro data suggest that DEHP-induced progesterone
decrease could be mediated by PPARG because the in vitro
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FIG. 8. PTGS2 and 3beta-HSD activities by CL collected from in vivo untreated (control) and DEHP in vivo treated rabbits at early, mid, and late stages of
pseudopregnancy. The in vitro acute effects of 15d-PGJ2 (PPARG agonist), DEHP, DEHP plus 15d-PGJ2, and DEHP plus T0070907 (PPARG antagonist)
were obtained on CL from in vivo untreated rabbits. Values are the means 6 SD of six replicates. Different letters above the bars indicate significantly
different values (P , 0.01) among control CL, and the asterisks indicate significantly different values (P , 0.01) versus the control.
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coincubation with DEHP plus 15d-PGJ2 showed that this
PPARG agonist counteracted the effects of the EDC. In
contrast, the present in vivo results do not support this idea
because DEHP affected progesterone production also in late
CL when PPARG protein and gene expression were at their
lowest level. The discrepancy between in vivo and in vitro data
may be explained, as mentioned above, by the possible
multiple effects of DEHP systemic in vivo administration.
Furthermore, we cannot exclude that the unchanged
progesterone in vitro secretion was a result of two concomitant
opposite phenomena and not necessary because DEHP uses the
PPARG pathway. An alternative hypothesis could be that
DEHP exerts its effect through other cellular pathways, for
example, that of aryl hydrocarbon receptor. This is an orphan
receptor expressed in ovary follicles and CL [49] that affects
steroid synthesis and is activated by phthalates [50]. Thus, in
our experiments DEHP would decrease progesterone by means
of aryl hydrocarbon receptor activation at the same time as
15d-PGJ2 stimulates this secretion after PPARG activation, a
situation that could also result in no significant differences in
progesterone levels between the two experimental groups.
The molecular mechanisms of PPARG in ovarian functions
are not well understood; one suggestion is that PPARG may
directly influence PTGS2 gene expression [15]. In fact, the
PTGS2 promoter region contains a PPARG response element
[51]. On the other hand, there are conflicting studies that report
that PPARG stimulates [51] and inhibits [52, 53] PTGS2 gene
expression. More recently, we have found that the PPARG
endogenous agonist down-regulated and its antagonist up-
regulated PTGS2 luteal activity at both early and mid
pseudopregnancy stages [24].
The present results show that DEHP affects PTGS2 protein
expression, decreasing the luteal cell immunostaining at late
stage, whereas this enzyme does not seem to be influenced by
DEHP treatment in early and mid-CL. It is interesting to note
that, in early and mid-CL, DEHP increased PTGS2 activity
with the concomitant decrease of PPARG gene expression,
whereas it did not affect immunoexpression of this enzyme. In
contrast, in late CL, DEHP decreased PPARG immunoexpres-
sion, whereas it did not influence PTGS2 activity and its
mRNA level. These conflicting data are difficult to explain;
perhaps DEHP at late stage uses other cellular pathways, but at
the moment, this is unknown. Our data, also demonstrated that
DEHP-induced PTGS2 up-regulation caused an increase of
PGF2alpha in vitro secretion by early and mid-CL, whereas
both PTGS1 activity and PGE2 release were not modified. The
PPARG agonist counteracted also the in vitro DEHP effects on
PTGS2 and PGF2alpha, so confirming the possible PPARG
mediation on DEHP activity.
In rabbit CL, PGE2-9-K has a modulator role that correlates
its enzymatic activity with negative PGE2 and positive
PGF2alpha synthesis, respectively [45]. Our data demonstrate
that DEHP decreases the PGE2-9-K immunostaining of luteal
cells in all the CL types compared to controls, whereas it did
not affect the activity of this enzyme in the same CL, as
reported in a previous study, showing that PGE2-9-K activity
was not modified by both 15d-PGJ2 and T0070907 in vitro
treatments in all the luteal stages [24].
While some studies indicated that the activity of 3beta-HSD
was inhibited by troglitazone, a member of the class of
thiazolidinediones, which are PPARG activators, in porcine
granulosa cells [54], other authors stated that thiazolidine-
diones treatment did not affect the 3beta-HSD mRNA levels in
porcine granulosa cells and protein levels in ovine granulosa
cells [55, 56]. The present results confirmed that PPARG
affects 3beta-HSD activity because 15d-PGJ
2
increased and
T0070907 decreased the activity of this enzyme in early and
mid-CL, as we have previous reported [23, 24]. Interestingly,
both the agonist and the antagonist of PPARG had no effects
on 3beta-HSD activity during the late luteal stage when the
immunopresence of this nuclear receptor reached its lowest
levels.
Our data indicated that DEHP did not modify the
immunopresence of 3beta-HSD in luteal cells, whereas the
activity of this enzyme diminished during early and mid stages.
The failure of DEHP to affect 3beta-HSD protein expression
and the concomitant effect on the activity of this enzyme
suggest that DEHP does not directly affect 3beta-HSD activity
directly, but rather through PPARG inhibition; indeed,
coincubation with 15d-PGJ2 counteracted the DEHP-induced
3beta-HSD down-regulation, as shown by the in vitro data on
progesterone and PGF2alpha secretions and PTGS2 activity.
Moreover, as noted above for progesterone, other alternative
DEHP-activated cellular mechanisms cannot be excluded.
An increasing body of converging experimental evidences
indicates that phthalates, including DEHP, cause a pleiotropic
range of effects, depending on tissue and species, and alter the
reproductive functions acting at different levels as a conse-
quence of their binding and activation of PPARG and
downstream effects on gene expression (for reviews, see [57,
58]). Interestingly, however, our present results show that the
in vitro effects induced by DEHP on rabbit luteal function are
opposite to those observed after treatment with the PPARG
agonist. In addition, DEHP was found to mimic the actions
induced by an antagonist of the receptor [24], suggesting that
the DEHP effects on PPARG-mediated events are controlled
by several cellular and molecular mechanisms, depending on
tissues and/or species.
In conclusion, our research demonstrates that DEHP has
notable effects on the activities of pseudopregnant rabbit CL,
favoring functional luteolysis, with a mechanism that seems to
involve the down-regulation of PPARG, the increase of PTGS2
activity and of PGF2alpha secretion, the down-regulation of
3beta-HSD, and, finally, the decrease of progesterone.
However, though the present data shed new light on possible
DEHP effects on physiological mechanisms regulating luteal
activity of mammals, further investigations are needed to better
understand the fine-tuning of this EDC in modifying CL life
span.
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